Eli Lilly plans to invest five billion dollars in a new manufacturing facility in Goochland County, Virginia. The investment aims to increase production of cancer treatments and biologics, including monoclonal antibodies and antibody drug conjugates. This plant will enhance U.S. drug manufacturing capacity, part of a broader strategy to re-shore pharmaceutical production amidst discussions of tariffs. The new site promises to boost the supply of vital medicines and support biologics development.